Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...